Tempus AI sued for securities law violations; class action lawsuit.

• Tempus AI faces class action lawsuit over alleged securities law violations • Shareholders who purchased securities between Aug 6, 2024, and May 27, 2025, are affected • Complaint alleges the company made false and misleading statements to the market • Transactions with affiliated entities and internally financed deals were exaggerated • Joint venture with SoftBank faced risk of being undermined due to round-tripping funds • Company acquired Ambry with a reputation for aggressive and potentially unethical business conduct • Public representations were materially false and misleading, according to the complaint.

San Diego, Aug. 11, 2025 — Tempus AI, Inc. (NASDAQ: TEM), a technology company advancing precision medicine through artificial intelligence, is facing a class action lawsuit alleging securities law violations. The lawsuit, captioned Shouse v. Tempus AI, Inc., No. 25-cv-06534 (N.D. Ill.), was filed by Robbins Geller Rudman & Dowd LLP, a prominent law firm specializing in securities fraud and shareholder litigation.

The lawsuit claims that Tempus AI made false and/or misleading statements and/or failed to disclose material information during the class period from August 6, 2024, to May 27, 2025. The alleged violations include:

1. Inflated Contract Agreements: The company is accused of inflating the value of contract agreements, many of which were with related parties, and included non-binding opt-ins and/or were self-funded.
2. Joint Venture with SoftBank: The credibility and substance of Tempus AI's joint venture with SoftBank Group Corporation was at risk due to the appearance of "round-tripping" capital to create revenue.
3. Acquisition of Ambry Genetics: Tempus AI-acquired Ambry Genetics Corporation had a business model based on aggressive and potentially unethical billing practices that risked scrutiny and unsustainability.
4. Financial Commitments from AstraZeneca: AstraZeneca PLC had reduced its financial commitments to Tempus AI through a questionable "pass-through payment" via a joint agreement between it, Tempus AI, and Pathos AI, Inc.
5. Public Statements: The company's public statements were materially false and misleading, according to the complaint.

Investors who purchased Tempus AI common stock during the class period have until August 12, 2025, to seek appointment as lead plaintiff. The lead plaintiff will act on behalf of all other class members in directing the lawsuit. Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder litigation, with a history of securing substantial monetary relief for investors [1].

Investor Alert

Investors are advised to contact the law firms involved in the case to seek further information and to determine if they qualify to participate. Robbins Geller Rudman & Dowd LLP can be reached at 800/449-4900 or via email at [Robbins Geller Rudman & Dowd LLP](https://www.rgrdlaw.com/cases-tempus-ai-inc-class-action-lawsuit-tem.html). Pomerantz LLP can be reached at Danielle Peyton at newaction@pomlaw.com or 646-581-9980. The Schall Law Firm can be reached at Brian Schall at 310-301-3335 or via email at bschall@schallfirm.com [2][3].

References

[1] https://www.prnewswire.com/news-releases/investor-deadline-tomorrow-robbins-geller-rudman--dowd-llp-announces-that-tempus-ai-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit---tem-302525397.html
[2] https://www.globenewswire.com/news-release/2025/08/09/3130471/1087/en/INVESTOR-ALERT-Pomerantz-Law-Firm-Reminds-Investors-with-Losses-on-their-Investment-in-Tempus-AI-Inc-of-Class-Action-Lawsuit-and-Upcoming-Deadlines-TEM.html
[3] https://www.morningstar.com/news/pr-newswire/20250811la48187/tem-investors-have-opportunity-to-lead-tempus-ai-inc-securities-fraud-lawsuit-with-the-schall-law-firm